Mucosal vaccination with M2e5x VLP decreases innate immune cell recruitments after influenza virus infection. by Young-Tae Lee (467116)

Overexpression of miR-219-5p in glioma cell lines decreased proliferation, anchorage independent growth and migration of glioma cells. by Soumya Alige Mahabala Rao (413479)

The T37A substitution increases both H5N6 M1 protein stability and H5N6 viral replication in mammals. by Chenxi Wang (284364)

Subjects:

Inhibition of GLS1 decreases the proportion of CCR6 and CXCR3 expressing CD4⁺ T cells. by Zeynep Sener (3146064)

“…BPTES and 968 significantly decrease the proportion of CCR6 expressing cells under normoxia both at day 3 and 5, whereas 968 but not BPTES decrease the proportion of CCR6 expressing cells under hypoxia both at day 3 and 5. …”

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Overexpression of cathepsin K in mice decreases collagen deposition and lung resistance in response to bleomycin-induced pulmonary fibrosis-1 by Mrigank Srivastava (94935)

Accumulated immature APP in response to IDN5706 is degraded by Atg5-dependent autophagy. by Viviana A. Cavieres (500139)

Overexpression of cathepsin K in mice decreases collagen deposition and lung resistance in response to bleomycin-induced pulmonary fibrosis-4 by Mrigank Srivastava (94935)